Arvinas
Bookmark
ShareArvinas is a company. It is located in New Haven, the United States and was founded in 2013. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: New Haven
- state: CT
- country: United States
- sector: Health Care
- industry: Biotechnology
- foundation year: 2013
- CEO: Dr. John G. Houston Ph.D.
Classified as: organization
Business
Arvinas is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,550,070 companies in our database.
- Assets: 1.6B $
- Debt: 6.8M $
- Employees: 280 people
- Free cash flow: 113.4M $
- Market cap: 2.3B $
- Revenues: 65.4M $
Stocks from Arvinas:
Talking Points
- Protein Degradation with PROTAC | Arvinas
- Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics.
- A revolutionary approach to protein degradation therapeutics. https://t.co/fEc6SErnkS
- Leading the way in targeted protein degradation therapeutics | Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Learn more about talking points
